Alder Biopharmaceuticals, Inc.. (ALDR) NASDAQ
$18.88 - (-)
Market Cap: -
As of 10/21/19 04:00 PM EDT. Market closed.
Alder Biopharmaceuticals, Inc.. (ALDR)
NASDAQ
$18.88
- (-)
Market Cap: -
As of 10/21/19 04:00 PM EDT. Market closed.
Add to Portfolio
Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers, develops and commercializes various therapeutic antibodies. Its product portfolio includes ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), ... read more
Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers, develops and commercializes various therapeutic antibodies. Its product portfolio includes ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine; and Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. read less
COMPANY PROFILE
Sector
Health Technology
Industry
Biotechnology
CEO Compensation (Base)
$187,480
CEO Compensation (Total)
$3.16M
Sector
Health Technology
Industry
Biotechnology
CEO
Robert W. Azelby
CEO Compensation (Base)
$187,480
CEO Compensation (Total)
$3.16M
URL
Address
11804 North Creek Parkway South, WA, Bothell, 98011.
PRICE CHART FOR ALDER BIOPHARMACEUTICALS, INC.
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
-
Previous Close
-
Days Range
- - -
52 week range
$8.39 - $19.12
Volume
0
Avg. Volume (30 days)
6,665,768
Market Cap
-
Dividend Yield
-
P/E
-
Shares Outstanding
0
Open
-
Previous Close
-
Days Range
- - -
52 week range
$8.39 - $19.12
Volume
0
Avg. Volume (30 days)
6,665,768
Market Cap
-
Dividend Yield
-
P/E
-
Shares Outstanding
0
FINANCIAL STATEMENTS FOR ALDER BIOPHARMACEUTICALS, INC.
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR ALDER BIOPHARMACEUTICALS, INC.
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| STRECK PAUL | Chief Medical Officer | Oct 11, 2019 | Option Exercise | $9.20 | 1,390 | 12,788 | 1,390 | Oct 24, 2019, 07:28 PM |
| STRECK PAUL | Chief Medical Officer | Oct 22, 2019 | Option Exercise | $18.00 | 1,390 | 25,020 | 0 | Oct 24, 2019, 07:28 PM |
| Lavelle Erin | Chief Operating Officer | Oct 22, 2019 | Option Exercise | $18.00 | 16,092 | 289,656 | 0 | Oct 24, 2019, 07:12 PM |
| Bucher James B | EVP & General Counsel | Oct 11, 2019 | Option Exercise | $9.20 | 904 | 8,317 | 12,058 | Oct 24, 2019, 07:10 PM |
| Bucher James B | EVP & General Counsel | May 31, 2019 | Option Exercise | $9.20 | 1,345 | 12,370 | 11,154 | Oct 24, 2019, 07:10 PM |
| Bucher James B | EVP & General Counsel | Oct 22, 2019 | Option Exercise | $18.00 | 27,677 | 498,186 | 0 | Oct 24, 2019, 07:10 PM |
| Hassler Randal | EVP, Pharmaceutical Ops. | Oct 22, 2019 | Option Exercise | $18.00 | 19,780 | 356,040 | 0 | Oct 24, 2019, 07:09 PM |
| Smith Jeffrey T L | Managing Director | Oct 22, 2019 | Option Exercise | $18.00 | 21,502 | 387,036 | 0 | Oct 24, 2019, 07:07 PM |
| YARNO WENDY L | Director | Oct 22, 2019 | Option Exercise | $18.00 | 5,000 | 90,000 | 0 | Oct 24, 2019, 07:05 PM |
| SIEGALL CLAY B | Director | Oct 22, 2019 | Option Exercise | $18.00 | 31,714 | 570,852 | 0 | Oct 24, 2019, 07:03 PM |
| Montgomery Alan Bruce | Director | Oct 22, 2019 | Option Exercise | $18.00 | 9,628 | 173,304 | 0 | Oct 24, 2019, 06:58 PM |
| Smith Jeffrey T L | Managing Director | Sep 16, 2019 | Option Exercise | $4.15 | 32,728 | 135,902 | 38,000 | Sep 18, 2019, 04:45 PM |
| Smith Jeffrey T L | Managing Director | Sep 16, 2019 | Sale | $18.44 | 32,728 | 603,504 | 5,272 | Sep 18, 2019, 04:45 PM |
| Hassler Randal | EVP, Pharmaceutical Ops. | Apr 25, 2019 | Sale | $13.85 | 1,738 | 24,067 | 5,434 | Apr 25, 2019, 06:55 PM |
| Benedict Larry | EVP and PAO | Apr 25, 2019 | Sale | $13.65 | 1,734 | 23,662 | 39,728 | Apr 25, 2019, 06:53 PM |
| Smith Jeffrey T L | Managing Director | Apr 25, 2019 | Option Exercise | $13.73 | 4,847 | 66,526 | 5,272 | Apr 25, 2019, 06:51 PM |
| Lavelle Erin | Chief Operating Officer | Apr 25, 2019 | Sale | $13.67 | 1,434 | 19,599 | 4,408 | Apr 25, 2019, 06:49 PM |
| Bucher James B | EVP & General Counsel | Apr 25, 2019 | Sale | $13.85 | 1,897 | 26,281 | 9,809 | Apr 25, 2019, 06:43 PM |
| Redmile Group, LLC | Director | Mar 04, 2019 | Option Exercise | $11.50 | 1,739,130 | 19,999,995 | 8,244,896 | Mar 06, 2019, 04:24 PM |
| Latham John A | Chief Scientific Officer | Nov 30, 2018 | Option Exercise | $9.35 | 487 | 4,553 | 244,180 | Feb 08, 2019, 04:47 PM |
| Bucher James B | EVP & General Counsel | Nov 30, 2018 | Option Exercise | $9.35 | 273 | 2,553 | 3,896 | Feb 08, 2019, 04:43 PM |
| Benedict Larry | EVP and PAO | May 31, 2018 | Option Exercise | $9.35 | 1,319 | 12,333 | 33,453 | Feb 08, 2019, 04:41 PM |
| Benedict Larry | EVP and PAO | Nov 30, 2018 | Option Exercise | $9.35 | 954 | 8,920 | 34,407 | Feb 08, 2019, 04:41 PM |
| Smith Jeffrey T L | Managing Director | Dec 03, 2018 | Option Exercise | $0.99 | 5,044 | 4,994 | 5,875 | Dec 04, 2018, 06:39 PM |
| Smith Jeffrey T L | Managing Director | Dec 03, 2018 | Sale | $13.84 | 5,044 | 69,826 | 831 | Dec 04, 2018, 06:39 PM |
| Bucher James B | Sr. VP & General Counsel | May 31, 2018 | Option Exercise | $9.35 | 2,000 | 18,700 | 3,623 | Nov 27, 2018, 05:35 PM |
| Smith Jeffrey T L | Managing Director | Nov 01, 2018 | Option Exercise | $0.99 | 5,040 | 4,990 | 5,871 | Nov 05, 2018, 05:47 PM |
| Smith Jeffrey T L | Managing Director | Nov 01, 2018 | Sale | $13.42 | 5,040 | 67,637 | 831 | Nov 05, 2018, 05:47 PM |
| Latham John A | Chief Scientific Officer | Nov 01, 2018 | Option Exercise | $9.12 | 25,002 | 227,954 | 268,695 | Nov 05, 2018, 05:43 PM |
| Latham John A | Chief Scientific Officer | Nov 01, 2018 | Sale | $13.42 | 25,002 | 335,589 | 245,012 | Nov 05, 2018, 05:43 PM |
| Smith Jeffrey T L | Managing Director | Oct 01, 2018 | Option Exercise | $0.99 | 5,040 | 4,990 | 5,871 | Oct 03, 2018, 06:33 PM |
| Smith Jeffrey T L | Managing Director | Oct 01, 2018 | Sale | $15.54 | 5,040 | 78,329 | 2,831 | Oct 03, 2018, 06:33 PM |
| Latham John A | Chief Scientific Officer | Oct 01, 2018 | Option Exercise | $4.36 | 24,999 | 109,108 | 268,692 | Oct 03, 2018, 06:31 PM |
| Latham John A | Chief Scientific Officer | Oct 01, 2018 | Sale | $15.44 | 24,999 | 386,006 | 250,247 | Oct 03, 2018, 06:31 PM |
| Smith Jeffrey T L | Managing Director | Sep 04, 2018 | Option Exercise | $0.99 | 5,040 | 4,990 | 5,871 | Sep 06, 2018, 05:08 PM |
| Smith Jeffrey T L | Managing Director | Sep 04, 2018 | Sale | $18.00 | 5,040 | 90,699 | 831 | Sep 06, 2018, 05:08 PM |
| Latham John A | Chief Scientific Officer | Sep 04, 2018 | Option Exercise | $3.46 | 24,999 | 86,622 | 268,692 | Sep 06, 2018, 05:05 PM |
| Latham John A | Chief Scientific Officer | Sep 04, 2018 | Sale | $17.99 | 24,999 | 449,680 | 243,693 | Sep 06, 2018, 05:05 PM |
| Smith Jeffrey T L | Managing Director | Aug 01, 2018 | Option Exercise | $0.99 | 5,040 | 4,990 | 5,871 | Aug 02, 2018, 05:48 PM |
| Smith Jeffrey T L | Managing Director | Aug 01, 2018 | Sale | $19.54 | 5,040 | 98,489 | 1,811 | Aug 02, 2018, 05:48 PM |
| Latham John A | Chief Scientific Officer | Aug 01, 2018 | Option Exercise | $3.46 | 24,999 | 86,622 | 268,692 | Aug 02, 2018, 05:40 PM |
| Latham John A | Chief Scientific Officer | Aug 01, 2018 | Sale | $19.55 | 24,999 | 488,768 | 243,693 | Aug 02, 2018, 05:40 PM |
| Smith Jeffrey T L | Managing Director | Jul 02, 2018 | Option Exercise | $1.38 | 12,161 | 16,739 | 12,992 | Jul 03, 2018, 05:28 PM |
| Smith Jeffrey T L | Managing Director | Jul 02, 2018 | Sale | $15.49 | 12,161 | 188,364 | 831 | Jul 03, 2018, 05:28 PM |
| Latham John A | Chief Scientific Officer | Jul 02, 2018 | Option Exercise | $3.46 | 24,999 | 86,622 | 268,692 | Jul 03, 2018, 05:22 PM |
| Latham John A | Chief Scientific Officer | Jul 02, 2018 | Sale | $15.48 | 24,999 | 387,002 | 243,693 | Jul 03, 2018, 05:22 PM |
| Latham John A | Chief Scientific Officer | Jun 01, 2018 | Option Exercise | $4.37 | 24,999 | 109,121 | 268,692 | Jun 05, 2018, 05:43 PM |
| Latham John A | Chief Scientific Officer | Jun 01, 2018 | Sale | $17.85 | 24,999 | 446,356 | 248,492 | Jun 05, 2018, 05:43 PM |
| Smith Jeffrey T L | Managing Director | Jun 01, 2018 | Option Exercise | $1.38 | 12,161 | 16,739 | 12,992 | Jun 05, 2018, 05:41 PM |
| Smith Jeffrey T L | Managing Director | Jun 01, 2018 | Sale | $17.85 | 12,161 | 217,127 | 1,931 | Jun 05, 2018, 05:41 PM |
| Litton Mark James | Chief Business Officer | Jun 01, 2018 | Option Exercise | $0.99 | 22,727 | 22,500 | 124,916 | Jun 05, 2018, 05:40 PM |
| Litton Mark James | Chief Business Officer | Jun 01, 2018 | Sale | $17.84 | 22,727 | 405,412 | 106,663 | Jun 05, 2018, 05:40 PM |
| Smith Jeffrey T L | Managing Director | May 16, 2018 | Option Exercise | $1.38 | 12,161 | 16,739 | 12,992 | May 18, 2018, 05:57 PM |
| Smith Jeffrey T L | Managing Director | May 16, 2018 | Sale | $15.03 | 12,161 | 182,758 | 831 | May 18, 2018, 05:57 PM |
| Latham John A | Chief Scientific Officer | Nov 30, 2017 | Option Exercise | $9.35 | 472 | 4,413 | 243,208 | Dec 18, 2017, 06:28 PM |
| Latham John A | Chief Scientific Officer | May 31, 2017 | Option Exercise | $13.09 | 333 | 4,359 | 242,736 | Dec 18, 2017, 06:28 PM |
| Bucher James B | Sr. VP & General Counsel | Nov 30, 2017 | Option Exercise | $9.35 | 1,623 | 15,175 | 1,623 | Dec 18, 2017, 06:25 PM |
| Litton Mark James | Chief Business Officer | Nov 13, 2017 | Option Exercise | $1.65 | 16,519 | 27,256 | 116,451 | Nov 15, 2017, 05:54 PM |
| Litton Mark James | Chief Business Officer | Nov 13, 2017 | Sale | $10.80 | 16,519 | 178,486 | 99,932 | Nov 15, 2017, 05:54 PM |
| SIEGALL CLAY B | Director | Nov 01, 2017 | Option Exercise | $1.30 | 27,270 | 35,496 | 31,714 | Nov 03, 2017, 05:48 PM |
| Litton Mark James | Chief Business Officer | Oct 16, 2017 | Option Exercise | $1.65 | 16,520 | 27,258 | 116,452 | Oct 18, 2017, 06:20 PM |
| Litton Mark James | Chief Business Officer | Oct 16, 2017 | Sale | $12.33 | 16,520 | 203,703 | 99,932 | Oct 18, 2017, 06:20 PM |
| YARNO WENDY L | Director | Jul 18, 2017 | Buy | $10.00 | 5,000 | 50,000 | 5,000 | Jul 18, 2017, 07:52 PM |
| DOW STEPHEN M | Director | Jul 18, 2017 | Buy | $10.00 | 25,000 | 250,000 | 307,190 | Jul 18, 2017, 07:50 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Jun 20, 2017 | Option Exercise | $0.99 | 585 | 579 | 1,416 | Jun 22, 2017, 06:12 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Jun 20, 2017 | Sale | $20.00 | 585 | 11,700 | 831 | Jun 22, 2017, 06:12 PM |
| Schatzman Randall C | President and CEO | Feb 09, 2017 | Option Exercise | $1.65 | 30,000 | 49,500 | 145,172 | Feb 13, 2017, 06:10 PM |
| Schatzman Randall C | President and CEO | Feb 09, 2017 | Sale | $25.03 | 30,000 | 750,756 | 115,172 | Feb 13, 2017, 06:10 PM |
| Benedict Larry | EVP and PAO | Nov 30, 2016 | Option Exercise | $20.20 | 742 | 14,988 | 30,989 | Jan 31, 2017, 05:32 PM |
| Schatzman Randall C | President and CEO | Nov 30, 2016 | Option Exercise | $20.20 | 404 | 8,161 | 115,172 | Jan 31, 2017, 05:23 PM |
| Litton Mark James | Chief Business Officer | Jan 18, 2017 | Option Exercise | $1.65 | 1,498 | 2,472 | 101,430 | Jan 20, 2017, 06:38 PM |
| Litton Mark James | Chief Business Officer | Jan 18, 2017 | Sale | $23.10 | 1,498 | 34,599 | 99,932 | Jan 20, 2017, 06:38 PM |
| Litton Mark James | Chief Business Officer | Jan 06, 2017 | Option Exercise | $1.34 | 6,800 | 9,113 | 106,732 | Jan 09, 2017, 05:49 PM |
| Litton Mark James | Chief Business Officer | Jan 05, 2017 | Option Exercise | $1.26 | 2,216 | 2,803 | 102,148 | Jan 09, 2017, 05:49 PM |
| Litton Mark James | Chief Business Officer | Jan 09, 2017 | Option Exercise | $1.65 | 500 | 825 | 100,432 | Jan 09, 2017, 05:49 PM |
| Litton Mark James | Chief Business Officer | Jan 06, 2017 | Sale | $23.02 | 6,800 | 156,520 | 99,932 | Jan 09, 2017, 05:49 PM |
| Litton Mark James | Chief Business Officer | Jan 05, 2017 | Sale | $23.00 | 2,216 | 50,972 | 99,932 | Jan 09, 2017, 05:49 PM |
| Litton Mark James | Chief Business Officer | Jan 09, 2017 | Sale | $23.00 | 500 | 11,500 | 99,932 | Jan 09, 2017, 05:49 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Dec 01, 2016 | Option Exercise | $1.65 | 3,000 | 4,950 | 3,831 | Dec 05, 2016, 06:47 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Dec 01, 2016 | Sale | $22.78 | 3,000 | 68,328 | 1,331 | Dec 05, 2016, 06:47 PM |
| Latham John A | Chief Scientific Officer | Dec 01, 2016 | Option Exercise | $1.65 | 3,636 | 5,999 | 246,039 | Dec 05, 2016, 06:46 PM |
| Latham John A | Chief Scientific Officer | Dec 01, 2016 | Sale | $22.78 | 3,636 | 82,812 | 242,903 | Dec 05, 2016, 06:46 PM |
| Latham John A | Chief Scientific Officer | Nov 09, 2016 | Option Exercise | $1.65 | 10,000 | 16,500 | 252,200 | Nov 14, 2016, 06:32 PM |
| Latham John A | Chief Scientific Officer | Nov 09, 2016 | Sale | $30.18 | 10,000 | 301,839 | 242,200 | Nov 14, 2016, 06:32 PM |
| Schatzman Randall C | President and CEO | Nov 07, 2016 | Option Exercise | $1.65 | 10,000 | 16,500 | 124,768 | Nov 09, 2016, 06:17 PM |
| Schatzman Randall C | President and CEO | Nov 07, 2016 | Sale | $25.16 | 10,000 | 251,605 | 114,768 | Nov 09, 2016, 06:17 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Nov 01, 2016 | Option Exercise | $1.65 | 3,000 | 4,950 | 3,000 | Nov 03, 2016, 06:39 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Nov 01, 2016 | Sale | $24.34 | 3,000 | 73,032 | 400 | Nov 03, 2016, 06:39 PM |
| Litton Mark James | Chief Business Officer | Oct 17, 2016 | Sale | $27.50 | 6,000 | 164,998 | 26,000 | Oct 19, 2016, 05:51 PM |
| Benedict Larry | EVP and PAO | May 31, 2016 | Option Exercise | $8.50 | 2,000 | 17,000 | 30,247 | Oct 11, 2016, 04:56 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Oct 03, 2016 | Option Exercise | $1.65 | 3,000 | 4,950 | 3,000 | Oct 05, 2016, 07:02 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Oct 03, 2016 | Sale | $31.14 | 3,000 | 93,415 | 702 | Oct 05, 2016, 07:02 PM |
| Schatzman Randall C | President and CEO | Oct 03, 2016 | Option Exercise | $1.26 | 8,181 | 10,349 | 122,949 | Oct 05, 2016, 06:54 PM |
| Schatzman Randall C | President and CEO | Oct 03, 2016 | Sale | $31.15 | 8,181 | 254,811 | 117,468 | Oct 05, 2016, 06:54 PM |
| Latham John A | Chief Scientific Officer | Oct 03, 2016 | Option Exercise | $1.65 | 10,000 | 16,500 | 252,200 | Oct 05, 2016, 06:53 PM |
| Latham John A | Chief Scientific Officer | Oct 03, 2016 | Sale | $31.32 | 10,000 | 313,152 | 248,449 | Oct 05, 2016, 06:53 PM |
| Latham John A | Chief Scientific Officer | Sep 01, 2016 | Option Exercise | $1.65 | 10,000 | 16,500 | 252,200 | Sep 06, 2016, 06:39 PM |
| Latham John A | Chief Scientific Officer | Sep 01, 2016 | Sale | $32.49 | 10,000 | 324,949 | 242,200 | Sep 06, 2016, 06:39 PM |
| Schatzman Randall C | President and CEO | Sep 01, 2016 | Option Exercise | $1.26 | 10,000 | 12,650 | 124,768 | Sep 06, 2016, 06:36 PM |
| Schatzman Randall C | President and CEO | Sep 01, 2016 | Sale | $32.48 | 10,000 | 324,820 | 114,768 | Sep 06, 2016, 06:36 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Sep 01, 2016 | Option Exercise | $1.65 | 3,000 | 4,950 | 3,000 | Sep 06, 2016, 06:34 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Sep 01, 2016 | Sale | $32.49 | 3,000 | 97,483 | 100 | Sep 06, 2016, 06:34 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Aug 15, 2016 | Option Exercise | $1.65 | 3,000 | 4,950 | 3,000 | Aug 17, 2016, 06:55 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Aug 15, 2016 | Sale | $31.17 | 3,000 | 93,512 | 0 | Aug 17, 2016, 06:55 PM |
| Schatzman Randall C | President and CEO | Aug 01, 2016 | Option Exercise | $1.26 | 10,000 | 12,650 | 124,768 | Aug 03, 2016, 06:42 PM |
| Schatzman Randall C | President and CEO | Aug 01, 2016 | Sale | $31.15 | 10,000 | 311,513 | 119,600 | Aug 03, 2016, 06:42 PM |
| Latham John A | Chief Scientific Officer | Aug 01, 2016 | Option Exercise | $1.65 | 10,000 | 16,500 | 252,200 | Aug 03, 2016, 06:33 PM |
| Latham John A | Chief Scientific Officer | Aug 01, 2016 | Sale | $31.19 | 10,000 | 311,948 | 245,806 | Aug 03, 2016, 06:33 PM |
| Latham John A | Chief Scientific Officer | Jul 27, 2016 | Option Exercise | $1.65 | 9,187 | 15,159 | 251,387 | Jul 28, 2016, 06:37 PM |
| Latham John A | Chief Scientific Officer | Jul 26, 2016 | Option Exercise | $1.65 | 813 | 1,341 | 243,013 | Jul 28, 2016, 06:37 PM |
| Latham John A | Chief Scientific Officer | Jul 27, 2016 | Sale | $30.15 | 9,187 | 277,023 | 242,200 | Jul 28, 2016, 06:37 PM |
| Latham John A | Chief Scientific Officer | Jul 26, 2016 | Sale | $30.00 | 813 | 24,392 | 242,200 | Jul 28, 2016, 06:37 PM |
| Schatzman Randall C | President and CEO | Jul 25, 2016 | Option Exercise | $1.26 | 10,000 | 12,650 | 124,768 | Jul 27, 2016, 06:19 PM |
| Schatzman Randall C | President and CEO | Jul 25, 2016 | Sale | $28.08 | 10,000 | 280,805 | 114,768 | Jul 27, 2016, 06:19 PM |
| Litton Mark James | Chief Business Officer | Jul 12, 2016 | Option Exercise | $0.38 | 25,000 | 9,625 | 99,567 | Jul 14, 2016, 07:14 PM |
| Litton Mark James | Chief Business Officer | Jun 13, 2016 | Sale | $28.94 | 6,000 | 173,664 | 28,200 | Jun 15, 2016, 07:02 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Jun 03, 2016 | Option Exercise | $1.26 | 16,090 | 20,354 | 16,090 | Jun 07, 2016, 07:32 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Jun 03, 2016 | Sale | $30.20 | 16,090 | 485,933 | 4,805 | Jun 07, 2016, 07:32 PM |
| Schatzman Randall C | President and CEO | Jun 01, 2016 | Option Exercise | $1.26 | 10,000 | 12,650 | 124,768 | Jun 03, 2016, 07:16 PM |
| Schatzman Randall C | President and CEO | Jun 01, 2016 | Sale | $29.65 | 10,000 | 296,544 | 116,733 | Jun 03, 2016, 07:16 PM |
| Latham John A | Chief Scientific Officer | Jun 01, 2016 | Option Exercise | $1.65 | 10,000 | 16,500 | 252,200 | Jun 03, 2016, 07:11 PM |
| Latham John A | Chief Scientific Officer | Jun 01, 2016 | Sale | $30.02 | 10,000 | 300,216 | 242,200 | Jun 03, 2016, 07:11 PM |
| Latham John A | Chief Scientific Officer | May 27, 2016 | Option Exercise | $1.26 | 6,401 | 8,097 | 248,601 | Jun 01, 2016, 07:53 PM |
| Latham John A | Chief Scientific Officer | May 31, 2016 | Option Exercise | $1.37 | 33,599 | 46,003 | 275,799 | Jun 01, 2016, 07:53 PM |
| Latham John A | Chief Scientific Officer | May 31, 2016 | Sale | $30.04 | 33,599 | 1,009,284 | 242,200 | Jun 01, 2016, 07:53 PM |
| Latham John A | Chief Scientific Officer | May 27, 2016 | Sale | $30.05 | 6,401 | 192,335 | 242,200 | Jun 01, 2016, 07:53 PM |
| Litton Mark James | Chief Business Officer | May 31, 2016 | Option Exercise | $0.38 | 19,720 | 7,592 | 94,287 | Jun 01, 2016, 07:49 PM |
| Litton Mark James | Chief Business Officer | May 27, 2016 | Option Exercise | $0.38 | 5,280 | 2,033 | 79,847 | Jun 01, 2016, 07:49 PM |
| Litton Mark James | Chief Business Officer | May 31, 2016 | Sale | $30.05 | 19,720 | 592,566 | 74,567 | Jun 01, 2016, 07:49 PM |
| Litton Mark James | Chief Business Officer | May 27, 2016 | Sale | $30.06 | 5,280 | 158,693 | 74,567 | Jun 01, 2016, 07:49 PM |
| Schatzman Randall C | President and CEO | May 23, 2016 | Option Exercise | $1.26 | 2,997 | 3,791 | 115,944 | May 24, 2016, 08:13 PM |
| Schatzman Randall C | President and CEO | May 20, 2016 | Option Exercise | $1.26 | 2,986 | 3,777 | 115,933 | May 24, 2016, 08:13 PM |
| Schatzman Randall C | President and CEO | May 24, 2016 | Option Exercise | $1.26 | 4,017 | 5,082 | 116,964 | May 24, 2016, 08:13 PM |
| Schatzman Randall C | President and CEO | May 23, 2016 | Sale | $28.01 | 2,997 | 83,952 | 112,947 | May 24, 2016, 08:13 PM |
| Schatzman Randall C | President and CEO | May 20, 2016 | Sale | $28.01 | 2,986 | 83,635 | 112,947 | May 24, 2016, 08:13 PM |
| Schatzman Randall C | President and CEO | May 24, 2016 | Sale | $28.03 | 4,017 | 112,588 | 112,947 | May 24, 2016, 08:13 PM |
| Schatzman Randall C | President and CEO | Apr 15, 2016 | Option Exercise | $0.73 | 14,024 | 10,227 | 126,971 | Apr 18, 2016, 06:40 PM |
| Schatzman Randall C | President and CEO | Apr 14, 2016 | Option Exercise | $0.38 | 11,462 | 4,413 | 124,409 | Apr 18, 2016, 06:40 PM |
| Schatzman Randall C | President and CEO | Apr 18, 2016 | Option Exercise | $1.26 | 4,514 | 5,710 | 117,461 | Apr 18, 2016, 06:40 PM |
| Schatzman Randall C | President and CEO | Apr 15, 2016 | Sale | $28.11 | 14,024 | 394,150 | 112,947 | Apr 18, 2016, 06:40 PM |
| Schatzman Randall C | President and CEO | Apr 14, 2016 | Sale | $28.01 | 11,462 | 321,075 | 112,947 | Apr 18, 2016, 06:40 PM |
| Schatzman Randall C | President and CEO | Apr 18, 2016 | Sale | $28.08 | 4,514 | 126,742 | 112,947 | Apr 18, 2016, 06:40 PM |
| Benedict Larry | Sr. VP Finance | Nov 30, 2015 | Option Exercise | $8.50 | 2,000 | 17,000 | 28,247 | Feb 02, 2016, 07:00 PM |
| Litton Mark James | Chief Business Officer | Jan 04, 2016 | Option Exercise | $0.38 | 25,000 | 9,625 | 98,718 | Jan 06, 2016, 08:40 PM |
| Litton Mark James | Chief Business Officer | Jan 04, 2016 | Sale | $31.40 | 25,000 | 784,951 | 81,427 | Jan 06, 2016, 08:40 PM |
| Latham John A | Chief Scientific Officer | Jan 04, 2016 | Option Exercise | $1.26 | 10,000 | 12,650 | 251,726 | Jan 06, 2016, 08:37 PM |
| Latham John A | Chief Scientific Officer | Jan 04, 2016 | Sale | $31.41 | 10,000 | 314,137 | 245,226 | Jan 06, 2016, 08:37 PM |
| Schatzman Randall C | President and CEO | Jan 04, 2016 | Option Exercise | $0.38 | 10,000 | 3,850 | 121,579 | Jan 06, 2016, 08:35 PM |
| Schatzman Randall C | President and CEO | Jan 04, 2016 | Sale | $31.47 | 10,000 | 314,747 | 113,599 | Jan 06, 2016, 08:35 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Dec 01, 2015 | Option Exercise | $0.38 | 4,272 | 1,645 | 4,272 | Dec 03, 2015, 09:02 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Dec 01, 2015 | Sale | $37.24 | 4,272 | 159,104 | 0 | Dec 03, 2015, 09:02 PM |
| Latham John A | Chief Scientific Officer | Dec 01, 2015 | Option Exercise | $0.38 | 4,550 | 1,752 | 246,276 | Dec 03, 2015, 09:00 PM |
| Latham John A | Chief Scientific Officer | Dec 01, 2015 | Sale | $37.24 | 4,550 | 169,452 | 241,726 | Dec 03, 2015, 09:00 PM |
| Schatzman Randall C | President and CEO | Dec 01, 2015 | Option Exercise | $0.38 | 10,000 | 3,850 | 121,579 | Dec 03, 2015, 08:59 PM |
| Schatzman Randall C | President and CEO | Dec 01, 2015 | Sale | $37.24 | 10,000 | 372,431 | 111,579 | Dec 03, 2015, 08:59 PM |
| DOW STEPHEN M | Director | Nov 30, 2015 | Sale | $37.11 | 88 | 3,266 | 0 | Dec 02, 2015, 05:56 PM |
| Latham John A | Chief Scientific Officer | Nov 02, 2015 | Option Exercise | $0.38 | 4,545 | 1,750 | 245,810 | Nov 04, 2015, 09:44 PM |
| Latham John A | Chief Scientific Officer | Nov 02, 2015 | Sale | $33.69 | 4,545 | 153,137 | 244,410 | Nov 04, 2015, 09:44 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Nov 02, 2015 | Option Exercise | $0.38 | 3,900 | 1,501 | 3,900 | Nov 04, 2015, 09:42 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Nov 02, 2015 | Sale | $33.67 | 3,900 | 131,299 | 2,400 | Nov 04, 2015, 09:42 PM |
| Schatzman Randall C | President and CEO | Nov 02, 2015 | Option Exercise | $0.38 | 10,000 | 3,850 | 119,921 | Nov 04, 2015, 09:40 PM |
| Schatzman Randall C | President and CEO | Nov 02, 2015 | Sale | $33.71 | 10,000 | 337,066 | 116,543 | Nov 04, 2015, 09:40 PM |
| Latham John A | Chief Scientific Officer | Oct 01, 2015 | Option Exercise | $0.38 | 4,545 | 1,750 | 245,810 | Oct 05, 2015, 06:21 PM |
| Latham John A | Chief Scientific Officer | Oct 01, 2015 | Sale | $32.26 | 4,545 | 146,603 | 241,510 | Oct 05, 2015, 06:21 PM |
| Litton Mark James | Chief Business Officer | Oct 01, 2015 | Sale | $32.27 | 7,500 | 242,002 | 73,479 | Oct 05, 2015, 06:19 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Oct 01, 2015 | Option Exercise | $0.38 | 3,900 | 1,501 | 3,900 | Oct 05, 2015, 06:16 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Oct 01, 2015 | Sale | $32.25 | 3,900 | 125,778 | 100 | Oct 05, 2015, 06:16 PM |
| Benedict Larry | Sr. VP Finance | Sep 24, 2015 | Option Exercise | $3.28 | 24,981 | 82,060 | 26,247 | Sep 28, 2015, 06:19 PM |
| Latham John A | Chief Scientific Officer | Sep 24, 2015 | Option Exercise | $0.99 | 31,818 | 31,500 | 241,265 | Sep 28, 2015, 06:14 PM |
| Litton Mark James | Chief Business Officer | Sep 24, 2015 | Option Exercise | $1.26 | 12,764 | 16,146 | 80,419 | Sep 28, 2015, 06:11 PM |
| Latham John A | Chief Scientific Officer | Sep 01, 2015 | Option Exercise | $0.38 | 4,545 | 1,750 | 213,992 | Sep 03, 2015, 06:09 PM |
| Latham John A | Chief Scientific Officer | Sep 01, 2015 | Sale | $38.52 | 4,545 | 175,059 | 210,347 | Sep 03, 2015, 06:09 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Sep 01, 2015 | Option Exercise | $0.38 | 3,900 | 1,501 | 3,900 | Sep 03, 2015, 06:01 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Sep 01, 2015 | Sale | $38.50 | 3,900 | 150,165 | 1,500 | Sep 03, 2015, 06:01 PM |
| SRB Associates IX L.P. | Affiliate | Aug 31, 2015 | Sale | $38.75 | 16,218 | 628,460 | 88 | Sep 02, 2015, 02:51 PM |
| DOW STEPHEN M | Director | Aug 31, 2015 | Sale | $38.75 | 16,218 | 628,460 | 282,278 | Sep 02, 2015, 02:51 PM |
| SRB Associates IX L.P. | Affiliate | Aug 12, 2015 | Sale | $40.03 | 97,109 | 3,887,409 | 1,811,970 | Aug 13, 2015, 07:51 PM |
| SRB Associates IX L.P. | Affiliate | Aug 11, 2015 | Sale | $40.40 | 115,358 | 4,660,763 | 1,909,079 | Aug 13, 2015, 07:51 PM |
| JAGGERS JOHN V | Affiliate | Aug 11, 2015 | Sale | $40.40 | 115,358 | 4,660,763 | 1,909,125 | Aug 13, 2015, 07:50 PM |
| JAGGERS JOHN V | Affiliate | Aug 12, 2015 | Sale | $40.03 | 97,109 | 3,887,409 | 1,812,016 | Aug 13, 2015, 07:50 PM |
| DOW STEPHEN M | Director | Aug 12, 2015 | Sale | $40.03 | 97,109 | 3,887,409 | 2,086,096 | Aug 13, 2015, 07:49 PM |
| DOW STEPHEN M | Director | Aug 11, 2015 | Sale | $40.40 | 115,358 | 4,660,763 | 2,183,205 | Aug 13, 2015, 07:49 PM |
| Latham John A | Chief Scientific Officer | Aug 03, 2015 | Option Exercise | $0.38 | 4,545 | 1,750 | 213,992 | Aug 05, 2015, 06:27 PM |
| Latham John A | Chief Scientific Officer | Aug 03, 2015 | Sale | $45.62 | 4,545 | 207,322 | 209,447 | Aug 05, 2015, 06:27 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Aug 03, 2015 | Option Exercise | $0.38 | 3,900 | 1,501 | 3,900 | Aug 05, 2015, 06:26 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Aug 03, 2015 | Sale | $45.64 | 3,900 | 178,003 | 0 | Aug 05, 2015, 06:26 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Jul 01, 2015 | Option Exercise | $0.38 | 3,900 | 1,501 | 3,900 | Jul 06, 2015, 06:05 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Jul 01, 2015 | Sale | $51.18 | 3,900 | 199,616 | 0 | Jul 06, 2015, 06:05 PM |
| Latham John A | Chief Scientific Officer | Jul 01, 2015 | Option Exercise | $0.38 | 4,545 | 1,750 | 213,992 | Jul 06, 2015, 06:02 PM |
| Latham John A | Chief Scientific Officer | Jul 01, 2015 | Sale | $51.13 | 4,545 | 232,381 | 209,447 | Jul 06, 2015, 06:02 PM |
| Litton Mark James | Chief Business Officer | Jul 01, 2015 | Sale | $51.10 | 7,500 | 383,219 | 67,655 | Jul 06, 2015, 05:59 PM |
| Benedict Larry | Sr. VP Finance | Jun 12, 2015 | Option Exercise | $1.65 | 25,454 | 41,999 | 26,720 | Jun 16, 2015, 06:15 PM |
| Benedict Larry | Sr. VP Finance | Jun 12, 2015 | Sale | $47.46 | 25,454 | 1,208,090 | 1,266 | Jun 16, 2015, 06:15 PM |
| Litton Mark James | Chief Business Officer | Jun 04, 2015 | Option Exercise | $0.38 | 25,000 | 9,625 | 100,155 | Jun 08, 2015, 07:05 PM |
| Litton Mark James | Chief Business Officer | Jun 04, 2015 | Sale | $44.27 | 25,000 | 1,106,853 | 75,155 | Jun 08, 2015, 07:05 PM |
| Latham John A | Chief Scientific Officer | Jun 04, 2015 | Option Exercise | $0.38 | 25,000 | 9,625 | 234,447 | Jun 08, 2015, 07:03 PM |
| Latham John A | Chief Scientific Officer | Jun 04, 2015 | Sale | $44.18 | 25,000 | 1,104,463 | 209,447 | Jun 08, 2015, 07:03 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Jun 01, 2015 | Option Exercise | $0.38 | 3,900 | 1,501 | 3,900 | Jun 03, 2015, 08:04 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Jun 01, 2015 | Sale | $41.53 | 3,900 | 161,969 | 0 | Jun 03, 2015, 08:04 PM |
| Latham John A | Chief Scientific Officer | Jun 01, 2015 | Option Exercise | $0.38 | 4,545 | 1,750 | 213,992 | Jun 03, 2015, 07:59 PM |
| Latham John A | Chief Scientific Officer | Jun 01, 2015 | Sale | $41.53 | 4,545 | 188,757 | 209,447 | Jun 03, 2015, 07:59 PM |
| Schatzman Randall C | President and CEO | May 26, 2015 | Option Exercise | $0.38 | 50,000 | 19,250 | 159,921 | May 28, 2015, 06:15 PM |
| Schatzman Randall C | President and CEO | May 26, 2015 | Sale | $38.96 | 50,000 | 1,948,085 | 109,921 | May 28, 2015, 06:15 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | May 22, 2015 | Option Exercise | $0.05 | 7,202 | 396 | 7,202 | May 26, 2015, 07:53 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | May 21, 2015 | Option Exercise | $0.05 | 54,616 | 3,004 | 54,616 | May 26, 2015, 07:53 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | May 21, 2015 | Sale | $38.92 | 54,616 | 2,125,496 | 0 | May 26, 2015, 07:53 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | May 22, 2015 | Sale | $38.47 | 7,202 | 277,027 | 0 | May 26, 2015, 07:53 PM |
| DOW STEPHEN M | Director | May 20, 2015 | Sale | $40.39 | 8,462 | 341,820 | 4,313,992 | May 21, 2015, 06:30 PM |
| Benedict Larry | Sr. VP Finance | May 19, 2015 | Option Exercise | $1.65 | 20,000 | 33,000 | 20,663 | May 21, 2015, 06:20 PM |
| Benedict Larry | Sr. VP Finance | May 19, 2015 | Sale | $38.86 | 20,000 | 777,196 | 663 | May 21, 2015, 06:20 PM |
| SRB Associates IX L.P. | 10% Owner | May 19, 2015 | Sale | $37.02 | 1,136,100 | 42,059,900 | 4,048,874 | May 21, 2015, 05:53 PM |
| DOW STEPHEN M | Director | May 21, 2015 | Sale | $65.69 | 20,000 | 1,313,846 | 314,203 | May 21, 2015, 03:34 PM |
| SIEGALL CLAY B | Director | May 14, 2015 | Option Exercise | $0.33 | 18,181 | 6,000 | 42,625 | May 18, 2015, 08:51 PM |
| SIEGALL CLAY B | Director | May 18, 2015 | Sale | $39.97 | 20,000 | 799,418 | 4,444 | May 18, 2015, 08:51 PM |
| SIEGALL CLAY B | Director | May 14, 2015 | Sale | $35.04 | 18,181 | 637,077 | 24,444 | May 18, 2015, 08:51 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | May 01, 2015 | Option Exercise | $0.38 | 3,900 | 1,501 | 3,900 | May 05, 2015, 06:22 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | May 01, 2015 | Sale | $25.67 | 3,900 | 100,130 | 0 | May 05, 2015, 06:22 PM |
| Latham John A | Chief Scientific Officer | May 01, 2015 | Option Exercise | $0.38 | 4,545 | 1,750 | 213,533 | May 05, 2015, 06:18 PM |
| Latham John A | Chief Scientific Officer | May 01, 2015 | Sale | $25.67 | 4,545 | 116,663 | 208,988 | May 05, 2015, 06:18 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Apr 01, 2015 | Option Exercise | $0.38 | 3,900 | 1,501 | 3,900 | Apr 03, 2015, 06:02 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Apr 01, 2015 | Sale | $27.43 | 3,900 | 106,995 | 0 | Apr 03, 2015, 06:02 PM |
| Litton Mark James | Chief Business Officer | Apr 01, 2015 | Sale | $27.41 | 7,500 | 205,552 | 74,359 | Apr 03, 2015, 05:58 PM |
| Latham John A | Chief Scientific Officer | Mar 30, 2015 | Option Exercise | $0.38 | 14,500 | 5,582 | 223,488 | Apr 01, 2015, 08:36 PM |
| Latham John A | Chief Scientific Officer | Apr 01, 2015 | Option Exercise | $0.38 | 4,545 | 1,750 | 213,533 | Apr 01, 2015, 08:36 PM |
| Latham John A | Chief Scientific Officer | Mar 30, 2015 | Sale | $30.20 | 14,500 | 437,909 | 208,988 | Apr 01, 2015, 08:36 PM |
| Latham John A | Chief Scientific Officer | Apr 01, 2015 | Sale | $27.42 | 4,545 | 124,609 | 208,988 | Apr 01, 2015, 08:36 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Mar 02, 2015 | Option Exercise | $0.38 | 3,900 | 1,501 | 3,900 | Mar 04, 2015, 05:35 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Mar 02, 2015 | Sale | $26.25 | 3,900 | 102,357 | 0 | Mar 04, 2015, 05:35 PM |
| Latham John A | Chief Scientific Officer | Mar 02, 2015 | Option Exercise | $0.38 | 4,545 | 1,750 | 213,533 | Mar 04, 2015, 05:32 PM |
| Latham John A | Chief Scientific Officer | Mar 02, 2015 | Sale | $26.26 | 4,545 | 119,340 | 208,988 | Mar 04, 2015, 05:32 PM |
| Benedict Larry | Sr. VP Finance | Nov 28, 2014 | Option Exercise | $8.50 | 663 | 5,636 | 663 | Jan 28, 2015, 06:09 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Jan 27, 2015 | Option Exercise | $0.38 | 1,200 | 462 | 1,200 | Jan 28, 2015, 06:01 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Jan 26, 2015 | Option Exercise | $0.38 | 2,700 | 1,039 | 2,700 | Jan 28, 2015, 06:01 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Jan 27, 2015 | Sale | $28.27 | 1,200 | 33,921 | 0 | Jan 28, 2015, 06:01 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Jan 26, 2015 | Sale | $27.89 | 2,700 | 75,316 | 0 | Jan 28, 2015, 06:01 PM |
| Litton Mark James | Chief Business Officer | Jan 27, 2015 | Sale | $28.52 | 2,300 | 65,602 | 81,859 | Jan 28, 2015, 05:56 PM |
| Litton Mark James | Chief Business Officer | Jan 26, 2015 | Sale | $28.03 | 5,200 | 145,732 | 84,159 | Jan 28, 2015, 05:56 PM |
| Latham John A | Chief Scientific Officer | Jan 27, 2015 | Option Exercise | $0.38 | 7,145 | 2,751 | 216,133 | Jan 28, 2015, 05:54 PM |
| Latham John A | Chief Scientific Officer | Jan 26, 2015 | Option Exercise | $0.38 | 7,900 | 3,041 | 216,888 | Jan 28, 2015, 05:54 PM |
| Latham John A | Chief Scientific Officer | Jan 26, 2015 | Sale | $27.98 | 7,900 | 221,008 | 208,988 | Jan 28, 2015, 05:54 PM |
| Latham John A | Chief Scientific Officer | Jan 27, 2015 | Sale | $28.73 | 7,145 | 205,278 | 208,988 | Jan 28, 2015, 05:54 PM |
| Schatzman Randall C | President and CEO | Jan 26, 2015 | Sale | $27.93 | 36,422 | 1,017,234 | 173,499 | Jan 28, 2015, 05:51 PM |
| Schatzman Randall C | President and CEO | Jan 27, 2015 | Sale | $28.71 | 63,578 | 1,825,165 | 109,921 | Jan 28, 2015, 05:51 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Nov 24, 2014 | Sale | $16.91 | 9,090 | 153,735 | 0 | Nov 25, 2014, 06:13 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Nov 21, 2014 | Sale | $15.71 | 20,000 | 314,118 | 9,090 | Nov 25, 2014, 06:13 PM |
| Litton Mark James | Chief Business Officer | Nov 20, 2014 | Sale | $15.63 | 30,000 | 469,011 | 88,484 | Nov 24, 2014, 06:37 PM |
| Delphi Management Partners VII, L.L.C. | 10% Owner | May 13, 2014 | Buy | $10.00 | 3,465 | 34,650 | 2,838,532 | May 15, 2014, 05:45 PM |
| Delphi Management Partners VII, L.L.C. | 10% Owner | May 13, 2014 | Buy | $10.00 | 346,535 | 3,465,350 | 2,835,067 | May 15, 2014, 05:45 PM |
| PAKIANATHAN DEEPIKA | Director | May 13, 2014 | Buy | $10.00 | 3,465 | 34,650 | 2,838,532 | May 15, 2014, 05:43 PM |
| PAKIANATHAN DEEPIKA | Director | May 13, 2014 | Buy | $10.00 | 346,535 | 3,465,350 | 2,835,067 | May 15, 2014, 05:43 PM |
| Montgomery Alan Bruce | Director | May 13, 2014 | Buy | $10.00 | 3,000 | 30,000 | 9,628 | May 15, 2014, 05:18 PM |
| Ventures West 8 Limited Partnership | 10% Owner | May 13, 2014 | Buy | $10.00 | 250,000 | 2,500,000 | 3,469,528 | May 15, 2014, 05:09 PM |
| Bridger Gary | Director | May 13, 2014 | Buy | $10.00 | 250,000 | 2,500,000 | 3,469,528 | May 15, 2014, 05:08 PM |
| Novo A/S | 10% Owner | May 13, 2014 | Buy | $10.00 | 550,000 | 5,500,000 | 3,201,183 | May 14, 2014, 04:24 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| STRECK PAUL | Chief Medical Officer | 10/11/2019 | 12,788 |
| STRECK PAUL | Chief Medical Officer | 10/22/2019 | 25,020 |
| Lavelle Erin | Chief Operating Officer | 10/22/2019 | 289,656 |
| Bucher James B | EVP & General Counsel | 10/11/2019 | 8,317 |
| Bucher James B | EVP & General Counsel | 05/31/2019 | 12,370 |
| Bucher James B | EVP & General Counsel | 10/22/2019 | 498,186 |
| Hassler Randal | EVP, Pharmaceutical Ops. | 10/22/2019 | 356,040 |
| Smith Jeffrey T L | Managing Director | 10/22/2019 | 387,036 |
| YARNO WENDY L | Director | 10/22/2019 | 90,000 |
| SIEGALL CLAY B | Director | 10/22/2019 | 570,852 |
| Montgomery Alan Bruce | Director | 10/22/2019 | 173,304 |
| Smith Jeffrey T L | Managing Director | 09/16/2019 | 135,902 |
| Smith Jeffrey T L | Managing Director | 09/16/2019 | 603,504 |
| Hassler Randal | EVP, Pharmaceutical Ops. | 04/25/2019 | 24,067 |
| Benedict Larry | EVP and PAO | 04/25/2019 | 23,662 |
| Smith Jeffrey T L | Managing Director | 04/25/2019 | 66,526 |
| Lavelle Erin | Chief Operating Officer | 04/25/2019 | 19,599 |
| Bucher James B | EVP & General Counsel | 04/25/2019 | 26,281 |
| Redmile Group, LLC | Director | 03/04/2019 | 19,999,995 |
| Latham John A | Chief Scientific Officer | 11/30/2018 | 4,553 |
| Bucher James B | EVP & General Counsel | 11/30/2018 | 2,553 |
| Benedict Larry | EVP and PAO | 05/31/2018 | 12,333 |
| Benedict Larry | EVP and PAO | 11/30/2018 | 8,920 |
| Smith Jeffrey T L | Managing Director | 12/03/2018 | 4,994 |
| Smith Jeffrey T L | Managing Director | 12/03/2018 | 69,826 |
| Bucher James B | Sr. VP & General Counsel | 05/31/2018 | 18,700 |
| Smith Jeffrey T L | Managing Director | 11/01/2018 | 4,990 |
| Smith Jeffrey T L | Managing Director | 11/01/2018 | 67,637 |
| Latham John A | Chief Scientific Officer | 11/01/2018 | 227,954 |
| Latham John A | Chief Scientific Officer | 11/01/2018 | 335,589 |
| Smith Jeffrey T L | Managing Director | 10/01/2018 | 4,990 |
| Smith Jeffrey T L | Managing Director | 10/01/2018 | 78,329 |
| Latham John A | Chief Scientific Officer | 10/01/2018 | 109,108 |
| Latham John A | Chief Scientific Officer | 10/01/2018 | 386,006 |
| Smith Jeffrey T L | Managing Director | 09/04/2018 | 4,990 |
| Smith Jeffrey T L | Managing Director | 09/04/2018 | 90,699 |
| Latham John A | Chief Scientific Officer | 09/04/2018 | 86,622 |
| Latham John A | Chief Scientific Officer | 09/04/2018 | 449,680 |
| Smith Jeffrey T L | Managing Director | 08/01/2018 | 4,990 |
| Smith Jeffrey T L | Managing Director | 08/01/2018 | 98,489 |
| Latham John A | Chief Scientific Officer | 08/01/2018 | 86,622 |
| Latham John A | Chief Scientific Officer | 08/01/2018 | 488,768 |
| Smith Jeffrey T L | Managing Director | 07/02/2018 | 16,739 |
| Smith Jeffrey T L | Managing Director | 07/02/2018 | 188,364 |
| Latham John A | Chief Scientific Officer | 07/02/2018 | 86,622 |
| Latham John A | Chief Scientific Officer | 07/02/2018 | 387,002 |
| Latham John A | Chief Scientific Officer | 06/01/2018 | 109,121 |
| Latham John A | Chief Scientific Officer | 06/01/2018 | 446,356 |
| Smith Jeffrey T L | Managing Director | 06/01/2018 | 16,739 |
| Smith Jeffrey T L | Managing Director | 06/01/2018 | 217,127 |
| Litton Mark James | Chief Business Officer | 06/01/2018 | 22,500 |
| Litton Mark James | Chief Business Officer | 06/01/2018 | 405,412 |
| Smith Jeffrey T L | Managing Director | 05/16/2018 | 16,739 |
| Smith Jeffrey T L | Managing Director | 05/16/2018 | 182,758 |
| Latham John A | Chief Scientific Officer | 11/30/2017 | 4,413 |
| Latham John A | Chief Scientific Officer | 05/31/2017 | 4,359 |
| Bucher James B | Sr. VP & General Counsel | 11/30/2017 | 15,175 |
| Litton Mark James | Chief Business Officer | 11/13/2017 | 27,256 |
| Litton Mark James | Chief Business Officer | 11/13/2017 | 178,486 |
| SIEGALL CLAY B | Director | 11/01/2017 | 35,496 |
| Litton Mark James | Chief Business Officer | 10/16/2017 | 27,258 |
| Litton Mark James | Chief Business Officer | 10/16/2017 | 203,703 |
| YARNO WENDY L | Director | 07/18/2017 | 50,000 |
| DOW STEPHEN M | Director | 07/18/2017 | 250,000 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 06/20/2017 | 579 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 06/20/2017 | 11,700 |
| Schatzman Randall C | President and CEO | 02/09/2017 | 49,500 |
| Schatzman Randall C | President and CEO | 02/09/2017 | 750,756 |
| Benedict Larry | EVP and PAO | 11/30/2016 | 14,988 |
| Schatzman Randall C | President and CEO | 11/30/2016 | 8,161 |
| Litton Mark James | Chief Business Officer | 01/18/2017 | 2,472 |
| Litton Mark James | Chief Business Officer | 01/18/2017 | 34,599 |
| Litton Mark James | Chief Business Officer | 01/06/2017 | 9,113 |
| Litton Mark James | Chief Business Officer | 01/05/2017 | 2,803 |
| Litton Mark James | Chief Business Officer | 01/09/2017 | 825 |
| Litton Mark James | Chief Business Officer | 01/06/2017 | 156,520 |
| Litton Mark James | Chief Business Officer | 01/05/2017 | 50,972 |
| Litton Mark James | Chief Business Officer | 01/09/2017 | 11,500 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 12/01/2016 | 4,950 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 12/01/2016 | 68,328 |
| Latham John A | Chief Scientific Officer | 12/01/2016 | 5,999 |
| Latham John A | Chief Scientific Officer | 12/01/2016 | 82,812 |
| Latham John A | Chief Scientific Officer | 11/09/2016 | 16,500 |
| Latham John A | Chief Scientific Officer | 11/09/2016 | 301,839 |
| Schatzman Randall C | President and CEO | 11/07/2016 | 16,500 |
| Schatzman Randall C | President and CEO | 11/07/2016 | 251,605 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 11/01/2016 | 4,950 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 11/01/2016 | 73,032 |
| Litton Mark James | Chief Business Officer | 10/17/2016 | 164,998 |
| Benedict Larry | EVP and PAO | 05/31/2016 | 17,000 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 10/03/2016 | 4,950 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 10/03/2016 | 93,415 |
| Schatzman Randall C | President and CEO | 10/03/2016 | 10,349 |
| Schatzman Randall C | President and CEO | 10/03/2016 | 254,811 |
| Latham John A | Chief Scientific Officer | 10/03/2016 | 16,500 |
| Latham John A | Chief Scientific Officer | 10/03/2016 | 313,152 |
| Latham John A | Chief Scientific Officer | 09/01/2016 | 16,500 |
| Latham John A | Chief Scientific Officer | 09/01/2016 | 324,949 |
| Schatzman Randall C | President and CEO | 09/01/2016 | 12,650 |
| Schatzman Randall C | President and CEO | 09/01/2016 | 324,820 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 09/01/2016 | 4,950 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 09/01/2016 | 97,483 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 08/15/2016 | 4,950 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 08/15/2016 | 93,512 |
| Schatzman Randall C | President and CEO | 08/01/2016 | 12,650 |
| Schatzman Randall C | President and CEO | 08/01/2016 | 311,513 |
| Latham John A | Chief Scientific Officer | 08/01/2016 | 16,500 |
| Latham John A | Chief Scientific Officer | 08/01/2016 | 311,948 |
| Latham John A | Chief Scientific Officer | 07/27/2016 | 15,159 |
| Latham John A | Chief Scientific Officer | 07/26/2016 | 1,341 |
| Latham John A | Chief Scientific Officer | 07/27/2016 | 277,023 |
| Latham John A | Chief Scientific Officer | 07/26/2016 | 24,392 |
| Schatzman Randall C | President and CEO | 07/25/2016 | 12,650 |
| Schatzman Randall C | President and CEO | 07/25/2016 | 280,805 |
| Litton Mark James | Chief Business Officer | 07/12/2016 | 9,625 |
| Litton Mark James | Chief Business Officer | 06/13/2016 | 173,664 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 06/03/2016 | 20,354 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 06/03/2016 | 485,933 |
| Schatzman Randall C | President and CEO | 06/01/2016 | 12,650 |
| Schatzman Randall C | President and CEO | 06/01/2016 | 296,544 |
| Latham John A | Chief Scientific Officer | 06/01/2016 | 16,500 |
| Latham John A | Chief Scientific Officer | 06/01/2016 | 300,216 |
| Latham John A | Chief Scientific Officer | 05/27/2016 | 8,097 |
| Latham John A | Chief Scientific Officer | 05/31/2016 | 46,003 |
| Latham John A | Chief Scientific Officer | 05/31/2016 | 1,009,284 |
| Latham John A | Chief Scientific Officer | 05/27/2016 | 192,335 |
| Litton Mark James | Chief Business Officer | 05/31/2016 | 7,592 |
| Litton Mark James | Chief Business Officer | 05/27/2016 | 2,033 |
| Litton Mark James | Chief Business Officer | 05/31/2016 | 592,566 |
| Litton Mark James | Chief Business Officer | 05/27/2016 | 158,693 |
| Schatzman Randall C | President and CEO | 05/23/2016 | 3,791 |
| Schatzman Randall C | President and CEO | 05/20/2016 | 3,777 |
| Schatzman Randall C | President and CEO | 05/24/2016 | 5,082 |
| Schatzman Randall C | President and CEO | 05/23/2016 | 83,952 |
| Schatzman Randall C | President and CEO | 05/20/2016 | 83,635 |
| Schatzman Randall C | President and CEO | 05/24/2016 | 112,588 |
| Schatzman Randall C | President and CEO | 04/15/2016 | 10,227 |
| Schatzman Randall C | President and CEO | 04/14/2016 | 4,413 |
| Schatzman Randall C | President and CEO | 04/18/2016 | 5,710 |
| Schatzman Randall C | President and CEO | 04/15/2016 | 394,150 |
| Schatzman Randall C | President and CEO | 04/14/2016 | 321,075 |
| Schatzman Randall C | President and CEO | 04/18/2016 | 126,742 |
| Benedict Larry | Sr. VP Finance | 11/30/2015 | 17,000 |
| Litton Mark James | Chief Business Officer | 01/04/2016 | 9,625 |
| Litton Mark James | Chief Business Officer | 01/04/2016 | 784,951 |
| Latham John A | Chief Scientific Officer | 01/04/2016 | 12,650 |
| Latham John A | Chief Scientific Officer | 01/04/2016 | 314,137 |
| Schatzman Randall C | President and CEO | 01/04/2016 | 3,850 |
| Schatzman Randall C | President and CEO | 01/04/2016 | 314,747 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 12/01/2015 | 1,645 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 12/01/2015 | 159,104 |
| Latham John A | Chief Scientific Officer | 12/01/2015 | 1,752 |
| Latham John A | Chief Scientific Officer | 12/01/2015 | 169,452 |
| Schatzman Randall C | President and CEO | 12/01/2015 | 3,850 |
| Schatzman Randall C | President and CEO | 12/01/2015 | 372,431 |
| DOW STEPHEN M | Director | 11/30/2015 | 3,266 |
| Latham John A | Chief Scientific Officer | 11/02/2015 | 1,750 |
| Latham John A | Chief Scientific Officer | 11/02/2015 | 153,137 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 11/02/2015 | 1,501 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 11/02/2015 | 131,299 |
| Schatzman Randall C | President and CEO | 11/02/2015 | 3,850 |
| Schatzman Randall C | President and CEO | 11/02/2015 | 337,066 |
| Latham John A | Chief Scientific Officer | 10/01/2015 | 1,750 |
| Latham John A | Chief Scientific Officer | 10/01/2015 | 146,603 |
| Litton Mark James | Chief Business Officer | 10/01/2015 | 242,002 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 10/01/2015 | 1,501 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 10/01/2015 | 125,778 |
| Benedict Larry | Sr. VP Finance | 09/24/2015 | 82,060 |
| Latham John A | Chief Scientific Officer | 09/24/2015 | 31,500 |
| Litton Mark James | Chief Business Officer | 09/24/2015 | 16,146 |
| Latham John A | Chief Scientific Officer | 09/01/2015 | 1,750 |
| Latham John A | Chief Scientific Officer | 09/01/2015 | 175,059 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 09/01/2015 | 1,501 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 09/01/2015 | 150,165 |
| SRB Associates IX L.P. | Affiliate | 08/31/2015 | 628,460 |
| DOW STEPHEN M | Director | 08/31/2015 | 628,460 |
| SRB Associates IX L.P. | Affiliate | 08/12/2015 | 3,887,409 |
| SRB Associates IX L.P. | Affiliate | 08/11/2015 | 4,660,763 |
| JAGGERS JOHN V | Affiliate | 08/11/2015 | 4,660,763 |
| JAGGERS JOHN V | Affiliate | 08/12/2015 | 3,887,409 |
| DOW STEPHEN M | Director | 08/12/2015 | 3,887,409 |
| DOW STEPHEN M | Director | 08/11/2015 | 4,660,763 |
| Latham John A | Chief Scientific Officer | 08/03/2015 | 1,750 |
| Latham John A | Chief Scientific Officer | 08/03/2015 | 207,322 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 08/03/2015 | 1,501 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 08/03/2015 | 178,003 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 07/01/2015 | 1,501 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 07/01/2015 | 199,616 |
| Latham John A | Chief Scientific Officer | 07/01/2015 | 1,750 |
| Latham John A | Chief Scientific Officer | 07/01/2015 | 232,381 |
| Litton Mark James | Chief Business Officer | 07/01/2015 | 383,219 |
| Benedict Larry | Sr. VP Finance | 06/12/2015 | 41,999 |
| Benedict Larry | Sr. VP Finance | 06/12/2015 | 1,208,090 |
| Litton Mark James | Chief Business Officer | 06/04/2015 | 9,625 |
| Litton Mark James | Chief Business Officer | 06/04/2015 | 1,106,853 |
| Latham John A | Chief Scientific Officer | 06/04/2015 | 9,625 |
| Latham John A | Chief Scientific Officer | 06/04/2015 | 1,104,463 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 06/01/2015 | 1,501 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 06/01/2015 | 161,969 |
| Latham John A | Chief Scientific Officer | 06/01/2015 | 1,750 |
| Latham John A | Chief Scientific Officer | 06/01/2015 | 188,757 |
| Schatzman Randall C | President and CEO | 05/26/2015 | 19,250 |
| Schatzman Randall C | President and CEO | 05/26/2015 | 1,948,085 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 05/22/2015 | 396 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 05/21/2015 | 3,004 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 05/21/2015 | 2,125,496 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 05/22/2015 | 277,027 |
| DOW STEPHEN M | Director | 05/20/2015 | 341,820 |
| Benedict Larry | Sr. VP Finance | 05/19/2015 | 33,000 |
| Benedict Larry | Sr. VP Finance | 05/19/2015 | 777,196 |
| SRB Associates IX L.P. | 10% Owner | 05/19/2015 | 42,059,900 |
| DOW STEPHEN M | Director | 05/21/2015 | 1,313,846 |
| SIEGALL CLAY B | Director | 05/14/2015 | 6,000 |
| SIEGALL CLAY B | Director | 05/18/2015 | 799,418 |
| SIEGALL CLAY B | Director | 05/14/2015 | 637,077 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 05/01/2015 | 1,501 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 05/01/2015 | 100,130 |
| Latham John A | Chief Scientific Officer | 05/01/2015 | 1,750 |
| Latham John A | Chief Scientific Officer | 05/01/2015 | 116,663 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 04/01/2015 | 1,501 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 04/01/2015 | 106,995 |
| Litton Mark James | Chief Business Officer | 04/01/2015 | 205,552 |
| Latham John A | Chief Scientific Officer | 03/30/2015 | 5,582 |
| Latham John A | Chief Scientific Officer | 04/01/2015 | 1,750 |
| Latham John A | Chief Scientific Officer | 03/30/2015 | 437,909 |
| Latham John A | Chief Scientific Officer | 04/01/2015 | 124,609 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 03/02/2015 | 1,501 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 03/02/2015 | 102,357 |
| Latham John A | Chief Scientific Officer | 03/02/2015 | 1,750 |
| Latham John A | Chief Scientific Officer | 03/02/2015 | 119,340 |
| Benedict Larry | Sr. VP Finance | 11/28/2014 | 5,636 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 01/27/2015 | 462 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 01/26/2015 | 1,039 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 01/27/2015 | 33,921 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 01/26/2015 | 75,316 |
| Litton Mark James | Chief Business Officer | 01/27/2015 | 65,602 |
| Litton Mark James | Chief Business Officer | 01/26/2015 | 145,732 |
| Latham John A | Chief Scientific Officer | 01/27/2015 | 2,751 |
| Latham John A | Chief Scientific Officer | 01/26/2015 | 3,041 |
| Latham John A | Chief Scientific Officer | 01/26/2015 | 221,008 |
| Latham John A | Chief Scientific Officer | 01/27/2015 | 205,278 |
| Schatzman Randall C | President and CEO | 01/26/2015 | 1,017,234 |
| Schatzman Randall C | President and CEO | 01/27/2015 | 1,825,165 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 11/24/2014 | 153,735 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 11/21/2014 | 314,118 |
| Litton Mark James | Chief Business Officer | 11/20/2014 | 469,011 |
| Delphi Management Partners VII, L.L.C. | 10% Owner | 05/13/2014 | 34,650 |
| Delphi Management Partners VII, L.L.C. | 10% Owner | 05/13/2014 | 3,465,350 |
| PAKIANATHAN DEEPIKA | Director | 05/13/2014 | 34,650 |
| PAKIANATHAN DEEPIKA | Director | 05/13/2014 | 3,465,350 |
| Montgomery Alan Bruce | Director | 05/13/2014 | 30,000 |
| Ventures West 8 Limited Partnership | 10% Owner | 05/13/2014 | 2,500,000 |
| Bridger Gary | Director | 05/13/2014 | 2,500,000 |
| Novo A/S | 10% Owner | 05/13/2014 | 5,500,000 |
Load More Insider Transactions
BUYBACK ANNOUNCEMENT(S) FOR ALDER BIOPHARMACEUTICALS, INC.
LOADING...